Table 1.
Comparison of baseline characteristics between patients with high and low TOP2A protein expression
| All patients | TOP2A protein expression | |||
|---|---|---|---|---|
| High | Low | P value | ||
| n = 434 (100%) | n = 127 (29.3%) | n = 307 (70.7%) | ||
| Median age (range) a | 45(26–80) | 45(26–80) | 45(26–80) | 0.869 |
| Age at surgery (yr) | 0.725 | |||
| ≤ 40 | 124(28.6) | 37 (29.1) | 87 (28.3) | |
| > 40,< 60 | 288 (66.3) | 82 (64.6) | 206 (67.1) | |
| > =65 | 22 (5.1) | 8 (6.3) | 14 (4.6) | |
| Menopausal status | 1.000 | |||
| Premenopausal | 323 (74.4) | 95 (74.8) | 228 (74.3) | |
| Postmenopausal | 111 (25.6) | 32 (25.2) | 79 (25.7) | |
| Breast surgery | 0.847 | |||
| Lumpectomy | 35 (8.1) | 11 (8.7) | 24 (7.8) | |
| Mastectomy | 399 (91.9) | 116 (91.3) | 283 (92.2) | |
| Pathologic tumor size (mm) | 0.244 | |||
| ≤ 20 | 176 (40.5) | 57 (44.9) | 119 (38.8) | |
| 21–50 | 249 (57.4) | 69 (54.3) | 180 (58.6) | |
| > 50 | 9 (2.1) | 1 (0.8) | 8 (2.6) | |
| Number of involved lymph nodes | 0.920 | |||
| 0 | 291 (67.1) | 87 (68.5) | 204 (66.5) | |
| 1 | 77 (17.7) | 22 (17.3) | 55 (17.9) | |
| 2 | 33 (7.6) | 10 (7.9) | 23 (7.5) | |
| 3 | 33 (7.6) | 8 (6.3) | 25 (8.1) | |
| Predominant histologic subtype | 0.765 | |||
| Ductal | 407 (93.8) | 118(92.9) | 289(94.1) | |
| Lobular | 13 (3.0) | 5 (3.9) | 8 (2.6) | |
| Other | 14 (3.2) | 4 (3.2) | 10 (3.3) | |
| Grade | 0.028 | |||
| 1–2 | 304 (70.0) | 79 (62.2) | 225 (73.3) | |
| 3 | 130 (30.0) | 48 (37.8) | 82 (26.7) | |
| Median Ki67 (range)b | 10(2–90) | 20(5–90) | 10 (2–80) | 0.018 |
| Ki67 | 0.119 | |||
| < 14% | 220 (50.7) | 59 (46.5) | 161 (52.4) | |
| ≥ 14%, < 20% | 14 (3.2) | 4 (3.1) | 10 (3.3) | |
| ≥ 20%,< 30% | 37 (8.5) | 7 (5.5) | 30 (9.8) | |
| ≥ 30% | 163 (37.6) | 57 (44.9) | 106 (34.5) | |
| Adjuvant CT | 0.869 | |||
| No | 50 (11.5) | 16 (12.6) | 34 (11.1) | |
| Anthracyclinec | 203 (46.3) | 58 (45.7) | 145 (47.2) | |
| Taxaned | 9 (2.1) | 2 (1.6) | 7 (2.3) | |
| Anthracycline + Taxanee | 172 (40.1) | 51 (40.1) | 121 (39.4) | |
| Adjuvant RT | 1.000 | |||
| Yes | 81 (18.7) | 24 (18.9) | 57 (18.6) | |
| No | 353 (81.3) | 103 (81.1) | 250 (81.4) | |
| Adjuvant ET | 0.877 | |||
| Tamoxifen/Toremifene | 395 (91.0) | 115 (90.6) | 280 (91.2) | |
| AIs | 15 (3.5) | 6 (4.7) | 9 (2.9) | |
| Tamoxifen/AIs | 24 (5.5) | 6 (4.7) | 18 (5.9) | |
| Ovarian function suppression | 1.000 | |||
| Yes | 14 (3.2) | 4 (3.1) | 10 (3.3) | |
| No | 420 (96.8) | 123 (96.9) | 297 (96.7) | |
Abbreviations: CT Chemotherapy, ET Endocrine therapy, RT Radiation, AIs Aromatase inhibitors
a,bData were presented as number (range)
cincluding: EC regimen in 38 patients, FEC regimen in 165 patients
dincluding: TC regimen in 9 patients
eincluding: EC followed by docetaxel or paclitaxel in 16 patients, FEC followed by docetaxel or paclitaxel in 17 patients, TEC regimen in 10 patients, TE regimen in 129 patients